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NOD/SCID mice and inosculate with murine vessels to participate
in murine systemic blood ﬂow. While CD34CD45 cells are
enriched in hematopoietic colony forming cell activity, only
CD34CD45- cells give rise to ECFC in vitro. Recent studies
indicate that ECFC can be derived from umbilical arterial and
venous endothelial cells as well as endothelium from several other
vascular sites. Thus, umbilical cord blood and blood vessels may be
sources of cells that can be used for vascular regeneration.
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DIFFERENTIATION OF UCB-DERIVED MULTI-LINEAGE PROGENITOR
CELLS INTO RESPIRATORY EPITHELIAL CELLS
David McKenna, MD University of Minnesota, Minneapolis, MN
Umbilical cord blood (UCB) recently has been examined for the
presence of stem cells capable of differentiating into cell types
representative of all three embryonic layers. The few groups re-
porting success have typically used hepatic differentiation for dem-
onstration of endodermal potential. We report differentiation of
human UCB-derived stem cells called multi-lineage progenitor
cells, or MLPCs, into respiratory epithelial cells. Using a cell
separation medium (PrepaCyte-MLPC; BioE, Inc.) and plastic
adherence, MLPCs were isolated from UCB units (American Red
Cross Cord Blood Program) and expanded. Cultures were grown
in MSCGM (Cambrex, Inc.) prior to addition of Small Airway
Growth Medium (SAGM; Cambrex, Inc.), a maintenance medium
designed for airway epithelium. Following an 8 day culture, cells
were characterized by light microscopy, transmission electron mi-
croscopy, immunoﬂuorescence (IF), and PCR. Differentiated cells
were characterized by an epithelioid morphology with lamellar
bodies, the organelles responsible for secretion of surfactant. IF
and PCR conﬁrmed presence of protein product and mRNA of
surfactant protein C, a protein highly speciﬁc for type II cells.
UCB-derived MLPCs were isolated and expanded and then dif-
ferentiated into respiratory epithelial cells using an off-the-shelf
medium designed for maintenance of fully differentiated respira-
tory epithelial cells. To the best of our knowledge, this is the ﬁrst
time human non-embryonic stem cells have been differentiated
into type II alveolar cells. Additional studies are ongoing to further
evaluate the cells and the possibilities for therapeutic applications.
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Yoshimura** Division of Cell Processing (CERES), The Institute of
Medical Science, The University of Tokyo, Tokyo, Japan; Cell Processing
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Although experimental and clinical trials using bone marrow
derived mesenchymal stem cells demonstrated promising results,
cells from other sources have also been explored. We report the
isolation, expansion and differentiation of mesenchymal stem cells
(MSCs) derived from human umbilical cord blood and compare
the results to those of MSCs derived from human bone marrow,
adipose tissue and chorionic villi of placenta. Though surface
antigens of these various MSCs did not show signiﬁcant differ-
ences, differentiation abilities were signiﬁcantly different among
these MSCs. Cord blood-derived MSCs (CB-MSCs) were isolated
from 70% of cord blood units processed within 5 hours and at least
60 ml in volume. In each case these MSCs differentiated with high
efﬁciency to chondrocyte lineages as well, or better, than those
MSCs derived from bone marrow (BM-MSCs), but adipose tissue-
derived MSCs (AD- MSCs) did not. In vivo transplantation of
CB-MSCs with scaffolds, atero-collagen for chondrocyte or
-TCP for osteocytes into nude mice resulted in generation of
chondrocyte-like tissue as well as bone. Co-culture of MSCs with
lymphocytes stimulated with phytohemagglutinin and mixed lym-
phocyte culture suppressed proliferation of stimulated lymphocytes
as well as BM-MSCs and AD-MSCs, indicating that CB-MSCs
had immune-suppressive effect. Thus, the CB-MSCs can be a
possible allogeneic cell source for regenerative medicine.
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REDUCED RISK OF LEUKEMIA RELAPSE AFTER DOUBLE UCB TRANS-
PLANTATION
Michael R. Verneris, MD University of Minnesota, Minneapolis, MN
Allogeneic hematopoietic cell transplantation (allo-HCT) is po-
tentially curative therapy for patients with high-risk or relapsed
acute leukemia. In the absence of a matched sibling donor, hema-
toipoietic progenitor cells can be obtained from either the bone
marrow (BM), peripheral blood (PB) or umbilical cord blood
(UCB) of volunteer donors. Compared to BM and PB, UCB has a
number of beneﬁts including the lack of collection risk to the
donor, the absence of donor attrition and rapid availability. UCB
also has less stringent requirements for HLA matching and in the
majority of patients a suitably matched donor can be identiﬁed.
However, the widespread applicability of UCB transplantation has
been constrained by the limited volume of blood contained in
within the umbilical cord. This small volume of blood translates
into limited numbers of mononuclear cells and CD34 progenitor
cells and the dose of these (per kg recipient body weight) is the
single most import variable for UCB outcome. Thus, UCB has
been reserved mainly for children. Recently, we have demonstrated
that the addition of a second, partially HLA matched UCB unit can
augment the cell dose; increasing both the rate and frequency of
donor engraftment in patients who would otherwise have an inad-
equate cell dose with in a single UCB unit. Interestingly, the
majority (60%) of recipients of double UCB transplantation
showed engraftment of a single UCB unit. By day 21 after trans-
plant, the second unit was not detected and presumably eradicated
due to immunological mechanisms. To date it is unknown whether
the addition of a second, partially matched UCB unit has any
impact on leukemia recurrence. We retrospectively reviewed the
outcomes of patients with acute leukemia who received myeloab-
lative conditioning chemotherapy followed by either single or
double UCB transplantation. The goal was to provide an adequate
cell dose/kg to patients. On this basis, patients received either
single (n72) or double UCB (n54) unit transplantation. Recip-
ients of two UCB units had a number of transplant related variables
which differed from single unit recipients. Not surprisingly, double
unit recipients were older and weighed more than single recipients.
There were no signiﬁcant differences between the single and dou-
ble recipient groups with respect to disease (AML vs. ALL) and
stage (CR1-2 vs. CR3-relapse). Most patients (2/3rds for each
group) were in CR1-2. The total dose of infused MNCs or CD34
cells was not different between the two groups (for double UCB
transplants this was the total of both UCB units). Two conditioning
regimens were used during the course of this study. Single unit
recipients received either TBI/Cytoxan/ATG followed by CSA/
Methylprednisone (n53) or Fludarabine/CTX/TBI followed by
CSA/MMF (n14). Recipients of double unit transplantation re-
ceived only the ﬂudarabine containing regimen. The kinetics of
engraftment and incidence of TRM were not different between the
two groups. Recipients of two UCB transplants had a signiﬁcantly
higher rate of aGVHD compared to recipients of single unit
transplantation (RR2.7, 0.01). The rate of cGVHD was not
different between recipients of single and double UCB transplan-
tation. The median follow up was 4.9 yrs (CI, 0.7-1.0) for single
unit recipients and 2 yrs (CD, 0.7-5) for double unit recipients.
Cox regression showed that the following variables were not asso-
ciated with relapse: recipient age, gender, HLA disparity, CMV
serostatus, cell dose, CD34 cell dose, CD3 cell dose, condition-
ing regimen, GVHD prophylaxis and aGVHD. However, recipi-
ents of two UCB units were less likely to experience relapse relative
to single unit recipients (RR0.4, p0.06). Subgroup analysis
showed that patients with early stage disease (CR1-2) beneﬁted
from double UCB transplant (RR0.2, p0.01). There was no
difference in relapse for the advance patients (CD3-relapse) in
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